CFP and age-related macular degeneration: However, irrespective if an anti-properdin antibody shows an effect on AMD progression in the present study, anti-properdin therapies offer the great advantage that they do not completely block the complement pathway, but instead slow down this pivotal cascade by retaining the balance of the local complement system.